[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Carolyn Rodriguez\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100560279","phase-1-pilot-study-of-rr-hnk-in-ocd-100560279",false,"NCT06575075","Pilot Study of RR-HNK in OCD","A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder","(HNKO)","Inclusion Criteria:\n\n* Ages 18-65\n* Meet the criteria for OCD diagnosis\n* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI\u002FCBT) or or had refused these treatments for individual reasons\n* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to ketamine\n* Any current or past medical\u002Fpsychiatric condition that makes participation unsafe in the opinion of the investigator or study physician\n* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n* Lifetime history of deep brain stimulation","ALL","18 Years","65 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.",[29],"Obsessive-Compulsive Disorder",[31,32,33,34],"OCD","AMPA receptor antagonist","hydroxynorketamine","ketamine metabolite","RECRUITING","2026-03-03",{"date":38,"type":39},"2026-03-05","ACTUAL",{"date":41,"type":39},"2026-01-23",{"date":43,"type":22},"2029-11-30",{"name":45,"class":46},"Carolyn Rodriguez","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100499481","phase-2-mdma-assisted-cbt-for-ocd-mdma-cbt4ocd-study-100499481","NCT05783817","MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study","MDMA-CBT4OCD","Inclusion Criteria:\n\n1. At least 18 years old\n2. Fluent in speaking and reading the predominantly used or recognized language of the study site\n3. Able to swallow pills\n4. Meet the criteria for OCD diagnosis\n5. YBOCS total score of at least 16\n6. Not on psychotropic medications 1 month prior to study enrollment\n7. Able to tolerate a treatment-free period\n8. Able to tolerate study procedures\n9. Failed at least 1 prior trial of standard first-line OCD treatment\n10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication dosing, therapy, and study procedures.\n\nExclusion Criteria:\n\n1. Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n2. Weigh less than 48 kilograms (kgs)\n3. Any current problem which, in the opinion of the investigator or study physician, might interfere with participation",{"count":57,"type":22},40,[26],"The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).",[29],[31,62,63,64],"MDMA","OCD CBT","Cognitive Behavioral Therapy",{"date":38,"type":39},{"date":67,"type":39},"2025-09-10",{"date":69,"type":22},"2026-12-01",{"name":45,"class":46},""]